Tower Research Capital (TRC)’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-111
| Closed | -$2K | – | 4273 |
|
|
2017
Q4 | $2K | Sell |
111
-4,859
| -98% | -$59.8K | ﹤0.01% | 3303 |
|
|
2017
Q3 | $59K | Buy |
4,970
+4,629
| +1,357% | +$51.9K | ﹤0.01% | 1826 |
|
|
2017
Q2 | $4K | Buy |
+341
| New | +$3.48K | ﹤0.01% | 2165 |
|
|
2017
Q1 | – | Sell |
-574
| Closed | -$7K | – | 4465 |
|
|
2016
Q4 | $7K | Buy |
574
+473
| +468% | +$6.6K | ﹤0.01% | 2910 |
|
|
2016
Q3 | $1K | Sell |
101
-871
| -90% | -$10.3K | ﹤0.01% | 3480 |
|
|
2016
Q2 | $11K | Buy |
+972
| New | +$10.9K | ﹤0.01% | 2774 |
|
|
2016
Q1 | – | Sell |
-3,612
| Closed | -$62K | – | 5461 |
|
|
2015
Q4 | $62K | Buy |
3,612
+1,979
| +121% | +$35.5K | 0.01% | 458 |
|
|
2015
Q3 | $32K | Buy |
1,633
+343
| +27% | +$7.86K | ﹤0.01% | 1353 |
|
|
2015
Q2 | $21K | Buy |
1,290
+1,037
| +410% | +$18K | ﹤0.01% | 2068 |
|
|
2015
Q1 | $4K | Sell |
253
-264
| -51% | -$4.09K | ﹤0.01% | 3476 |
|
|
2014
Q4 | $7K | Sell |
517
-1,870
| -78% | -$19.8K | ﹤0.01% | 2511 |
|
|
2014
Q3 | $16K | Buy |
2,387
+1,831
| +329% | +$12.2K | ﹤0.01% | 2513 |
|
|
2014
Q2 | $4K | Buy |
+556
| New | +$3.93K | ﹤0.01% | 3083 |
|
|
2013
Q4 | – | Sell |
-834
| Closed | -$5K | – | 5189 |
|
|
2013
Q3 | $5K | Sell |
834
-4,161
| -83% | -$26K | ﹤0.01% | 3710 |
|
|
2013
Q2 | $33K | Buy |
+4,995
| New | +$39.6K | ﹤0.01% | 1270 |
|
Other funds holding SCMP
Tower Research Capital (TRC)'s SCMP Position: Q1 2018 in Review
Tower Research Capital (TRC) sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 111 shares — an estimated $2K sold.
Tower Research Capital (TRC) first reported a position in SCMP in Q2 2013 and held it in 15 quarters. The position peaked at $62K in Q4 2015. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.
- Tower Research Capital (TRC) reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
- Tower Research Capital (TRC) sold 111 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $2K.
- Tower Research Capital (TRC) first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2013 and held it in 15 quarters.
- Tower Research Capital (TRC)'s Sucampo Pharmaceuticals, Inc. position peaked at $62K in Q4 2015.
- 3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2018, filed 15 May 2018.